[go: up one dir, main page]

MX2023004611A - Comprimido de desintegracion oral que comprende un compuesto derivado de benzimidazol y procedimiento de preparacion del mismo. - Google Patents

Comprimido de desintegracion oral que comprende un compuesto derivado de benzimidazol y procedimiento de preparacion del mismo.

Info

Publication number
MX2023004611A
MX2023004611A MX2023004611A MX2023004611A MX2023004611A MX 2023004611 A MX2023004611 A MX 2023004611A MX 2023004611 A MX2023004611 A MX 2023004611A MX 2023004611 A MX2023004611 A MX 2023004611A MX 2023004611 A MX2023004611 A MX 2023004611A
Authority
MX
Mexico
Prior art keywords
preparation
derivative compound
orally disintegrating
disintegrating tablet
benzimidazole derivative
Prior art date
Application number
MX2023004611A
Other languages
English (en)
Inventor
Min Jung Kim
Tae Keun Cho
Eun Kyung Jeon
Young Dae Cho
Sun Young Park
Da Som Lim
Original Assignee
Hk Inno N Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hk Inno N Corp filed Critical Hk Inno N Corp
Publication of MX2023004611A publication Critical patent/MX2023004611A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un comprimido de desintegración oral que incluye un compuesto derivado de benzimidazol y un procedimiento de preparación del mismo.
MX2023004611A 2020-10-23 2021-10-21 Comprimido de desintegracion oral que comprende un compuesto derivado de benzimidazol y procedimiento de preparacion del mismo. MX2023004611A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200138712 2020-10-23
PCT/KR2021/014853 WO2022086238A1 (en) 2020-10-23 2021-10-21 Orally disintegrating tablet comprising benzimidazole derivative compound and preparation method thereof

Publications (1)

Publication Number Publication Date
MX2023004611A true MX2023004611A (es) 2023-05-08

Family

ID=79283599

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004611A MX2023004611A (es) 2020-10-23 2021-10-21 Comprimido de desintegracion oral que comprende un compuesto derivado de benzimidazol y procedimiento de preparacion del mismo.

Country Status (14)

Country Link
US (1) US20230381109A1 (es)
EP (1) EP4232001A4 (es)
JP (2) JP7626914B2 (es)
KR (2) KR102748218B1 (es)
CN (1) CN116507318A (es)
AR (1) AR123872A1 (es)
AU (1) AU2021364255B2 (es)
CA (1) CA3196459A1 (es)
GE (2) GEP20257787B (es)
MX (1) MX2023004611A (es)
UA (1) UA130203C2 (es)
UY (1) UY39479A (es)
WO (1) WO2022086238A1 (es)
ZA (1) ZA202305506B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025002519A1 (en) * 2023-06-29 2025-01-02 Fertin Pharma A/S Oral tablet with improved uniformity of content of actives
KR20250167166A (ko) * 2024-05-21 2025-12-01 주식회사 다산제약 무정형 테고프라잔을 포함하는 약제학적 조성물 및 이의 제조방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1664036T3 (da) * 2003-09-03 2012-02-13 Pfizer Benzimidazolonforbindelser med 5-HT4-receptoragonistisk virkning
CN1679525A (zh) * 2005-01-12 2005-10-12 复旦大学 复方对乙酰氨基酚口腔崩解片
BRPI0620081B8 (pt) 2005-12-19 2021-05-25 Pfizer composto e composição farmacêutica.
US20090258897A1 (en) * 2008-04-11 2009-10-15 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
KR101080001B1 (ko) * 2009-01-19 2011-11-04 보령제약 주식회사 졸피뎀 또는 그의 약제학적으로 허용되는 염을 포함하는 구강 속붕해정
JP5802898B2 (ja) * 2009-07-09 2015-11-04 ラクオリア創薬株式会社 消化管運動異常が関与する疾患を治療するためのアシッドポンプ拮抗剤
CN103169705A (zh) * 2011-12-23 2013-06-26 重庆医药工业研究院有限责任公司 一种含有氯苯那敏和右美沙芬的复方口腔崩解片
SI3305291T1 (sl) * 2015-06-08 2021-08-31 Hk Inno.N Corporation Uporabe benzimidazolnega derivata za nočno izločanje kisline
CN105534928A (zh) * 2015-12-18 2016-05-04 北京万全德众医药生物技术有限公司 含有伊曲茶碱的口腔崩解片及其制备方法
CN106074406A (zh) * 2016-06-12 2016-11-09 佛山市腾瑞医药科技有限公司 一种富马酸沃诺拉赞分散片及其制备方法
KR101829706B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
KR101849125B1 (ko) * 2016-12-12 2018-04-16 동화약품주식회사 프로톤 펌프 저해제를 포함하는 고체 분산체, 이의 제조방법 및 이를 포함하는 구강 붕해정
KR101960357B1 (ko) * 2016-12-26 2019-03-20 씨제이헬스케어 주식회사 벤즈이미다졸 유도체를 포함하는 신규한 제제
KR101914388B1 (ko) * 2017-09-05 2018-11-02 김경재 감미질이 개선된 효소처리 스테비아 조성물이 함유된 감미료
US11058633B2 (en) * 2018-05-17 2021-07-13 Fertin Pharma A/S Disintegrating oral tablet suitable for active pharmaceutical ingredients
JOP20190198A1 (ar) * 2018-08-28 2020-02-28 Hk Inno N Corp تركيبة صيدلانية تشتمل على عامل مضاد للصفيحات ومثبط إفراز حمض معدي
EP3955927A4 (en) * 2019-04-18 2023-06-07 Thomas Julius Borody COMPOSITIONS AND METHODS FOR TREATING, AMOUNTING AND PREVENTING H. PYLORI INFECTIONS

Also Published As

Publication number Publication date
CN116507318A (zh) 2023-07-28
EP4232001A4 (en) 2024-09-18
JP7626914B2 (ja) 2025-02-05
KR20250004202A (ko) 2025-01-07
US20230381109A1 (en) 2023-11-30
AU2021364255B2 (en) 2025-02-13
WO2022086238A1 (en) 2022-04-28
AR123872A1 (es) 2023-01-18
JP2025038168A (ja) 2025-03-18
AU2021364255A9 (en) 2024-06-27
CA3196459A1 (en) 2022-04-28
GEAP202516257A (en) 2025-04-25
GEP20257787B (en) 2025-08-11
AU2021364255A1 (en) 2023-06-22
EP4232001A1 (en) 2023-08-30
KR20220054211A (ko) 2022-05-02
UA130203C2 (uk) 2025-12-17
JP2023547092A (ja) 2023-11-09
UY39479A (es) 2021-11-30
ZA202305506B (en) 2025-10-29
KR102748218B1 (ko) 2024-12-31

Similar Documents

Publication Publication Date Title
ZA202305506B (en) Orally disintegrating tablet comprising benzimidazole derivative compound and preparation method thereof
SA522431869B1 (ar) مركبات بروتين-1 المتفاعل مع المستقبل تثبيطية وطرق عملها واستخدامها
PH12019500375A1 (en) A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MX393554B (es) Métodos de fabricación, composiciones y aplicaciones médicas de productos farmacéuticos de cannabis administrables oralmente.
MX2017003518A (es) Estimuladores de guanilato ciclasa soluble (sgc).
MA43518B1 (fr) 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase
PH12022550537A1 (en) Rip1 inhibitory compounds and methods for making and using the same.
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
CL2012000024A1 (es) Composicion farmaceutica que comprende 100 a 2000 mg de metformina y 10 a 300 mg de un compuesto inhibidor de sglt-2 derivado de glucopiranosil fenil sustituidos, celulosa microcristalina, un aglutinante y croscaramelosa.
MY196572A (en) Amino-Methyl Piperidine Derivative as Kinase Inhibitor
MX2019013792A (es) Sistema de produccion modular para formulaciones.
TR201721505A2 (tr) Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon
EP4129406A4 (en) NEW BENZIMIDAZOLE DERIVATIVE
PH12021550883A1 (en) Crystalline salts of a plasma kallikrein inhibitor
GEP20135747B (en) Method of benzonorbornenes production
AU2019322713A8 (en) Novel medicament for treating inflammatory bowel disease
GEP20247673B (en) Pharmaceutical composition comprising benzimidazole derivative compound
EP4056638A4 (en) COMPOSITION OF CELLULOSE, TABLET AND ORODISPERSIBLE TABLET
ZA202206266B (en) Pd-l1 antagonist compound
MA39877A (fr) Formes solides d'un composé pharmaceutiquement actif
MY207182A (en) Pharmaceutical composition comprising benzimidazole derivative compound
IN2014MU00859A (es)
MX2021009261A (es) Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.
MX2021001063A (es) Dispersion solida de derivado de hidantoina.
IN2013MU03422A (es)